Aldeyra Therapeutics, Inc.
ALDX
$2.76
$0.103.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -15.81M | -15.11M | -16.85M | -8.08M | -4.75M |
| Total Depreciation and Amortization | 64.40K | 63.00K | 61.60K | 60.60K | 66.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 842.00K | 2.75M | 1.45M | 1.44M | -729.60K |
| Change in Net Operating Assets | 2.87M | 4.32M | 2.11M | -3.39M | 5.92M |
| Cash from Operations | -12.04M | -7.97M | -13.22M | -9.97M | 500.40K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.56M | 5.26M | -18.24M | -30.38M | 0.00 |
| Cash from Investing | -1.56M | 5.26M | -18.24M | -30.38M | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -292.50K | -- | -- | -- | -1.04M |
| Issuance of Common Stock | 350.30K | 19.90K | 0.00 | 18.20K | 30.20K |
| Repurchase of Common Stock | -- | -- | -- | -- | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -50.00K | -217.30K | -- | -- | -- |
| Cash from Financing | 7.80K | -197.40K | 0.00 | 18.20K | -1.01M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.59M | -2.91M | -31.46M | -40.33M | -511.90K |